• Home
  • NEW DAY MEDICINE
  • 5 (79) 2025
  • 233 -5 (79) 2025 - Abdurahmаnov M.M., Bakaev. I.K. - MODERN THERAPEUTIC STRATEGIES FOR SUPPRESSING THE INFLAMMATORY PROCESS IN ATHEROSCLEROSIS

233 -5 (79) 2025 - Abdurahmаnov M.M., Bakaev. I.K. - MODERN THERAPEUTIC STRATEGIES FOR SUPPRESSING THE INFLAMMATORY PROCESS IN ATHEROSCLEROSIS

MODERN THERAPEUTIC STRATEGIES FOR SUPPRESSING THE INFLAMMATORY PROCESS IN ATHEROSCLEROSIS

Abdurahmаnov M.M. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Bakaev. I.K. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Boltaev S.S. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Olimov J.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The main links of the pathogenesis of the atherosclerotic process are presented with an emphasis on the possibility of its drug correction. The results of the CANTOS study on the effect of the monoclonal antibody kanakinumab, an IL-1ß inhibitor, on the incidence of cardiovascular complications in people who have suffered a myocardial infarction and have elevated levels of C-reactive protein are presented. The effect of low doses of methotrexate on cardiovascular outcomes in patients with myocardial infarction or multivessel lesion and concomitant diabetes mellitus or metabolic syndrome was discussed (CIRT study). Studies of the effectiveness of colchicine in the prevention of cardiovascular complications in patients with coronary heart disease are presented. It has been shown that blocking the inflammatory cascade plays an important role in slowing the progression of atherosclerosis and reducing the residual risk in patients with pre-existing cardiovascular diseases.

Key words: atherosclerosis, inflammation, colchicine, canakinumab, prevention.

First page

1155

Last page

1160

For citation:Abdurahmаnov M.M., Bakaev. I.K., Boltaev S.S., Olimov J.O. - MODERN THERAPEUTIC STRATEGIES FOR SUPPRESSING THE INFLAMMATORY PROCESS IN ATHEROSCLEROSIS//New Day in Medicine 5(79)2025 1155-1160 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

  1. Кардиоваскулярная профилактика. Российские национальные рекомендации. Российское кардиологическое общество, Национальное общество профилактической кардиологии. Москва. 2022. 356 с.
  2. Коваленко В.Н., Талаева Т.В., Братусь В.В. Холестерин и атеросклероз: традицион¬ные взгляды и современные представления. Укр. кардюл. журн. 2010; 3: 7-35
  3. Насонов Е.Л., Попкова Т.В. Противовоспалительная терапия атеросклероза - вклад и уроки ревматологии. Научно-практическая ревматология. 2017; 55 (5): 465-73.
  4. Полиморфизмы генов, ассоциированные с нарушением липидного обмена у людей молодого возраста с риском внезапной сердечной смерти / В. А. Качнов, Е. В. Крюков, С. Н. Колюбаева [и др.] // Казанский медицинский журнал. – 2021. – Т. 102, № 6. – С. 805-814
  5. Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022. Vol. 27, № 7. 5155.
  6. Antiinflammatory therapy with canakinumab for atherosclerotic disease / P.M. Ridker [et al.] // N. Engl. J. Med. 2017. № 377. Р. 1119–1131.
  7. Colchicine in patients with chronic coronary disease / S.M. Nidorf [et al.] // N. Engl. J. Med. 2020. № 383. Р. 1838–1847.
  8. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials / M. Samuel [et al.] Can. J. Cardiol. 2021. Vol. 37, № 5. Р. 776-785
  9. Colchicine in сardiovascular disease: in depth review / S.G. Deftereos [et al.] Circulation. 2022. Vol. 145, № 1. Р. 61–78.
  10. Guo H., Callaway J.B., Ting JP-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics // Nat. Med. 2015. № 21. Р. 677–687.
  11. Liuzzo G, Goronzy JJ, Yang H et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-8.
  12. Low-dose methotrexate for the prevention of atherosclerotic events / P.M. Ridker [et al.] // N. Engl. J. Med. 2019. № 380. Р. 752–762.
  13. Maseri A, Cianflone D. Inflammation in acute coronary syndromes. Eur Heart J 2002; 4 (Suppl. B): 8-13, 60.
  14. Moreno PR, Purushothaman RK, Fuster V, O’Connor WN. Increased incidence of internal elastic lamina rupture and intimal changes in complex atherosclerotic lesions: Understan¬ding the remodeling paradox and plaque disruption. J Am Coll Cardiol 2002; 39: 249-51.
  15. Nidorf M. Low dose colchicine for secondary prevention of cardiovascular disease (The LoDoCo Trial). J Am Coll Cardiol 2013; 61: 404-10.
  16. Proteolytic processing of interleukin-1 family cytokines: variations on a common theme / I.S. Afonina, C. Muller, S.J. Martin, R Beyaert // Immunity. 2015. № 42. Р. 991–1004.
  17. Rajamaki K, Lappalainen J, Oorni K et al. Cholesterol crystals activate the NLRP3 inflam- masome in human macrophages: a novel link between cholesterol metabolism and inflam¬mation. PLoS One 2010; 5 (7): e11765.
  18. Ridker P.M. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? // Circulation. 2020. № 141. Р. 787–789.
  19. Targeting cardiovascular inflammation: next steps in clinical translation / P.R. Lawler [et al.] Eur. Heart J. 2021. № 42. Р. 113–131.
  20. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of co¬ronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-40.

    file

    download